Yungpo Su, MD
Hematology & Oncology · Omaha, NENPI 1457322166
Payments from drug & device makers
Across 371 payments — averaging $3159.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$635K
- Merck$288K
- Pfizer$105K
- GSK$87K
- Exelixis Inc.$53K
- E.r. Squibb & Sons, L.L.C.$3K
- plus $230 from 11 others
Across 31 payments — averaging $146.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$5K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 183 | $635,181 |
| Merck | 99 | $288,150 |
| Pfizer | 17 | $105,405 |
| GSK | 40 | $87,240 |
| Exelixis Inc. | 18 | $53,396 |
| E.r. Squibb & Sons, L.L.C. | 3 | $2,664 |
| Dendreon Pharmaceuticals LLC | 1 | $48 |
| AbbVie | 1 | $32 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $22 |
| KARL Storz Endoscopy-america | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Array Biopharma Inc | 1 | $15 |
| Tersera Therapeutics LLC | 1 | $15 |
| Sanofi | 1 | $13 |
| Bristol Myers Squibb | 1 | $13 |
| Gilead | 1 | $12 |
How this compares
$1,172,265 in reported general payments places this provider in the 80th percentile of 73 hematology & oncology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Omaha
- Luke NordquistOmaha$29.3M
- Ralph HaukeOmaha$12.1M
- Margaret BlockOmaha$8.3M
- Stefano TarantoloOmaha$3.7M
- Julie VoseOmaha$3.5M
- Robert BociekOmaha$3M
- Vijaya BhattOmaha$2.2M
- Mojtaba AkhtariOmaha$1.9M
- Mary WellsOmaha$1.6M
- Robert LangdonOmaha$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.